Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.64 | N/A | +31.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.64 | N/A | +31.91% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism regarding ongoing projects. They noted the importance of continued focus on their clinical developments.
Management highlighted the progress in their clinical trials.
They emphasized their commitment to advancing their pipeline despite current challenges.
The earnings report shows that Protagonist Therapeutics exceeded expectations on EPS, which is a positive sign for investors. However, the stock reaction was slightly negative, declining by 0.13%. This could indicate that investors are looking for more clarity on revenue and future guidance, which was not provided in this report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TAKE-TWO INTERACTIVE
Nov 7, 2022